跳至主要内容
临床试验/EUCTR2005-003997-74-DK
EUCTR2005-003997-74-DK进行中(未招募)1 期

Depletion of regulatory T-lymphocytes by intratumoral injection of antibodies.

Rigshospitalet0 个研究点目标入组 30 人开始时间: 2006年1月10日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Histopathologically verified cancer with metastasis. No further conventional anti-cancer treatment options.
  • Radiological visualisation of cancer/metastasis localisation must enable direct or ultrasonography mediated intratumoral injection
  • Cancer diseases preferred:
  • 1. liver, primary and secondary.
  • 2. mammary cancer
  • 3. sarcomas
  • 4. melanomas
  • 5. prostate
  • 6. kidney, hypernefroma
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Expected lifetime < 3 months
  • ECOG 3-4.
  • Ongoing infection
  • < 4 weeks from prior immunosuppressive therapy
  • Billirubin >2 times upper normal value
  • ASAT/ALAT >2 times upper normal value
  • abnormal creatinine
  • < 4 weeks from major surgery
  • positive pregnancy test
  • No use of safe barrier contraception
  • Steroid treatment <4 weeks from start of CT
  • Participation in other experimental treatments.

研究者

相似试验